Annals of Oncology 14:1673-1676, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value
Departments of 1 Medicine and 2 Clinical Oncology, Queen Mary Hospital, Hong Kong; Departments of 3 Radiotherapy and 4 Pathology, Queen Elizabeth Hospital, Hong Kong, People’s Republic of China
Received 10 February 2003; revised 14 April 2003; accepted 11 August 2003
Nasal NK/T-cell lymphoma is an Epstein–Barr virus-related, highly aggressive but localized disease in Orientals. The median survival is <1 year. Here, we update our experience on 18 patients treated with autologous stem cell transplantation (ASCT). Two patients died of mucositis and septicemia during ASCT. Relapse occurred in nine cases, including six local relapses. Compared with patients treated in remission, all patients treated in active or disseminated disease died of early relapse. Within this cohort, there was no significant survival difference between patients treated in first (CR1, n = 7) or second (CR2, n = 5) complete remissions. However, among consecutive cases analyzed, the patients receiving ASCT at CR1 showed a trend towards better overall survival compared with historical matched controls (P = 0.064). Disease relapse beyond 6 months was not seen after ASCT. Our retrospective data suggest that ASCT in CR1 is a viable consolidation therapy for local-stage NK/T lymphoma, but a randomized trial is needed to prove any definite survival benefit. For patients with relapsed, refractory or extranasal disease, early consideration for allogeneic transplantation and alternative therapy may be warranted.
Key words: autologous stem cell transplantation, nasal NK/T lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Suzuki, J. Suzumiya, M. Yamaguchi, S. Nakamura, J. Kameoka, H. Kojima, M. Abe, T. Kinoshita, T. Yoshino, K. Iwatsuki, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type Ann. Onc., October 22, 2009; (2009) mdp418v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-y. Au, D. D. Weisenburger, T. Intragumtornchai, S. Nakamura, W.-S. Kim, I. Sng, J. Vose, J. O. Armitage, R. Liang, and for the International Peripheral T-Cell Lymphoma P Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project Blood, April 23, 2009; 113(17): 3931 - 3937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M E Cabrera, Y Eizuru, T Itoh, C Koriyama, Y Tashiro, S Ding, S Rey, S Akiba, and A Corvalan Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile J. Clin. Pathol., June 1, 2007; 60(6): 656 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, et al. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey Ann. Onc., May 1, 2006; 17(5): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type Blood, December 1, 2005; 106(12): 3785 - 3790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Y. Au, S.-Y. Ma, C.-S. Chim, C. Choy, F. Loong, A. K. W. Lie, C. C. K. Lam, A. Y. H. Leung, E. Tse, C.-C. Yau, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years Ann. Onc., February 1, 2005; 16(2): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Y. Au, A. Pang, C. Choy, C.-S. Chim, and Y.-L. Kwong Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients Blood, July 1, 2004; 104(1): 243 - 249. [Abstract] [Full Text] [PDF]
|
|